Freedom And Capital Drive Intarcia Down Independent Path
With a lucrative and unique royalty financing deal and positive first results from its global Phase III diabetes study, Intarcia has emerged as one of the biotech industry’s most valuable private companies and is in position to control its own destiny. It just may disrupt the type 2 diabetes market in the process.
You may also be interested in...
Investments in endocrine/metabolic disease-focused medtech companies reached a four-year high in 2015. Biopharma companies grabbed the majority of the funds that have been raised since 2012, and among medtechs, those focused on diabetes fared best.
Intarcia Therapeutics' fundraising is all the more impressive because it is an anomaly in the endocrine diseases space, as a June 11 report from the Biotechnology Industry Organization suggests.
Biotechs remain voracious consumers of capital, but tapping the equity markets is often prohibitively dilutive. Royalty financing can provide lower-cost-of-capital funding while putting a price on assets the market often ignores. This cash can also allow biotechs to hold onto R&D projects longer, eventually pushing up the price of licensing deals. But although royalty financiers are eager, they are limited in the amount of risk they are willing to take; new players in the business though may nevertheless increase competition and drive prices up.